We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| MannKind Corporation | NASDAQ:MNKD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.23% | 4.32 | 3.85 | 4.38 | 4.45 | 4.225 | 4.35 | 1,897,796 | 05:00:03 |
From May 2023 to May 2024
Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.
| DATE/TIMES: | MONDAY, JUNE 12, 2023 |
| 10:00 a.m. – 11:00 a.m. | |
| LOCATION: | MannKind |
| 40 Taylor Street (Danbury, CT) | |
| VISUALS/SOUND: | - Governor Lamont tours facility with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella |
| - Construction underway on “clean rooms” and spray dry equipment in new manufacturing space | |
| - Demonstration of MannKind’s innovative Technosphere® particle and device technologies | |
| - Production personnel producing the particle technology used as part of our inhaled insulin (Afrezza®) as well as Tyvaso DPI | |
| MANNKIND: | MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. |
| CONTACT: | MannKind Corporate Communications |
| Christie Iacangelo (on-site) | |
| (818) 292-3500 (mobile) | |
| ciacangelo@mnkd.com |
1 Year MannKind Chart |
1 Month MannKind Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
